9 Publications
2018
NFM-01. NF105: A PHASE II PROSPECTIVE STUDY OF CABOZANTINIB (XL184) FOR PLEXIFORM NEUROFIBROMAS IN SUBJECTS WITH NEUROFIBROMATOSIS TYPE 1: A NEUROFIBROMATOSIS CLINICAL TRIAL CONSORTIUM (NFCTC) STUDY
Shih, Chie-SchinShih, Chie-SchinShih, Chie SchinBlakely, JaishriBlakely, JaishriBlakely, JaishriClapp, WadeClapp, WadeClapp, WadeWolters, PamWolters, PamWolters, PamDombi, EvaDombi, EvaDombi, EvaCutter, GaryCutter, GaryCutter, GaryUllrich, NicholeUllrich, NicholeUllrich, NicholeAllen, JeffreyAllen, JeffreyAllen, JeffreyPacker, RogerPacker, RogerPacker, RogerGoldman, StewartGoldman, StewartGoldman, StewartGutmann, DavidGutmann, DavidGutmann, DavidPlotkin, ScottPlotkin, ScottPlotkin, ScottRosser, TenaRosser, TenaRosser, TenaRobertson, KentRobertson, KentRobertson, KentWidemann, BrigitteWidemann, BrigitteWidemann, BrigitteKorf, BruceKorf, BruceKorf, BruceFisher, MichaelFisher, Michael and Fisher, Michael
Neuro-Oncology, vol. 20, (no. suppl_2), pp. i142, 20180622. | Journal Article
2017
RARE-19. MULTICENTER, PHASE 2 STUDY OF BEVACIZUMAB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS 2 AND PROGRESSIVE VESTIBULAR SCHWANNOMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY
Plotkin, ScottTonsgard, JamesUllrich, NicoleAllen, JeffreyBlakeley, JashriRosser, TenaCampian, JianClapp, WadeFisher, MichaelCutter, GaryKorf, BrucePacker, RogerThomas, Coretta and Karjannis, Matthias
Neuro-Oncology, vol. 19, (no. suppl_6), pp. vi215, 2017-11-06. | Journal Article
 
The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis
Blakeley, Jaishri OBlakeley, Jaishri OBakker, AnnetteBakker, AnnetteBarker, AnneBarker, AnneClapp, WadeClapp, WadeFerner, RosalieFerner, RosalieFisher, Michael JFisher, Michael JGiovannini, MarcoGiovannini, MarcoGutmann, David HGutmann, David HKarajannis, Matthias AKarajannis, Matthias AKissil, Joseph LKissil, Joseph LLegius, EricLegius, EricLloyd, Alison CLloyd, Alison CPacker, Roger JPacker, Roger JRamesh, VijayaRamesh, VijayaRiccardi, Vincent MRiccardi, Vincent MStevenson, David AStevenson, David AUllrich, Nicole JUllrich, Nicole JUpadhyaya, MeenaUpadhyaya, MeenaStemmer‐Rachamimov, Anat and Stemmer-Rachamimov, Anat
American Journal of Medical Genetics Part A, vol. 173, (no. 6), pp. 1721, June 2017. | Journal Article
2016
Phase II Study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN)
Gross, Andrea MBaldwin, AndreaDombi, EvaWolters, PamelaWhitcomb, PatriciaHolmblad, MarielleMartin, StaciFisher, Michael JKim, AeRangWeiss, Brian DPaul, Scott MClapp, WadeFarrell, KathleenSmith, MichaeleFontana, JosephBrofferio, AlessandraSteinberg, Seth MDoyle, Laurence A and Widemann, Brigitte C
Journal of Clinical Oncology, vol. 34, (no. 15_suppl), pp. TPS10586, 2016-05-20. | Journal Article
 
Phase II trial of the MEK1/2 inhibitor selumetinib (AZD6244) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs)
Bradford, DianaWhitcomb, PatriciaDombi, EvaChen, Alice PBaldwin, AndreaWolters, PamelaMartin, StaciGlod, JohnDerdak, JoanneO'Sullivan Coyne, Geraldine HelenCowen, Edward WHolmblad, MarielleTrepel, JaneWood, Bradford JPaul, Scott MClapp, WadeJohnson, Gary LRubinstein, LarryDoyle, L. Austin and Widemann, Brigitte C
Journal of Clinical Oncology, vol. 34, (no. 15_suppl), pp. TPS2596, 2016-05-20. | Journal Article
2014
Abstract LB-79: PRC2 loss amplifies Ras-driven transcription and sensitizes cancers to bromodomain inhibitor-based combination therapies
Raedt, Thomas DBeert, ElinePasmant, EricLuscan, ArmelleBrems, HildeOrtonne, NicolasHelin, KristianMautner, VictorKehrer-Sawatski, HildegardClapp, WadeBradner, JamesUpadhyaya, MeenaVidaud, MichelLegius, Eric and Cichowski, Karen
Cancer Research, vol. 74, (no. 19 Supplement), pp. LB-79, 2014-10-01. | Journal Article
 
PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies
De Raedt, ThomasDe Raedt, ThomasBeert, ElineBeert, ElinePasmant, EricPasmant, EricLuscan, ArmelleLuscan, ArmelleBrems, HildeBrems, HildeOrtonne, NicolasOrtonne, NicolasHelin, KristianHelin, KristianHornick, Jason LHornick, Jason LMautner, VictorMautner, VictorKehrer-Sawatzki, HildegardKehrer-Sawatzki, HildegardClapp, WadeClapp, WadeBradner, JamesBradner, JamesVidaud, MichelVidaud, MichelUpadhyaya, MeenaUpadhyaya, MeenaLegius, EricLegius, EricCichowski, Karen and Cichowski, Karen
Nature, vol. 514, (no. 7521), pp. 251, 2014-Oct-09. | Journal Article
2013
Abstract 355: Generation of a murine model of Neurofibromatosis Type 2 that accurately recapitulates the spontaneous development of vestibular and spinal schwannomas found in NF2 patients
Gehlhausen, Jeff RPark, Su JungShew, MatthewClapp, Wade and Yates, Charles
Cancer Research, vol. 73, (no. 8 Supplement), pp. 355, 2013-04-15. | Journal Article
2004
Neurofibromatosis Type 1 (NF1), a Tumor Suppressor Gene, Is Synergistically Activated by RUNX1, C/EBPαa and ETS2 and Specifically Repressed by the T(8;21) Fusion Protein in Acute Myeloid Leukemia
Yang, GenyanKhalaf, WaleedClapp, Wade D and Hiebert, Scott W
Blood, vol. 104, (no. 11), pp. 2551, 2004-11-16. | Journal Article